Litcius/Paper detail

HPV‐associated oropharyngeal cancer de‐escalation strategies and trials: Past failures and future promise

Kaveh Zakeri, Lara Dunn, Nancy Y. Lee

2021Journal of Surgical Oncology25 citationsDOIOpen Access PDF

Abstract

HPV-associated oropharynx squamous cell carcinomas are radiosensitive and chemosensitive, thus, portending a favorable prognosis. Treatment de-intensification strategies aim to reduce toxicity while maintaining efficacy. Although approaches that have substituted cisplatin with cetuximab or omitted chemotherapy have not been successful, Transoral Robotic Surgery with de-intensified adjuvant therapy has been promising. Additionally, personalized approaches are taking advantage of tumor biology and utilizing tumor reduction or hypoxia on imaging as a predictive marker to successfully de-escalate radiotherapy and chemotherapy.

Topics & Concepts

CetuximabMedicineOncologyDe-escalationChemotherapyRadiation therapyInternal medicineTransoral robotic surgeryCisplatinHead and neck cancerAdjuvantCancerSurgeryColorectal cancerHead and Neck Cancer StudiesHead and Neck Surgical OncologySalivary Gland Tumors Diagnosis and Treatment
HPV‐associated oropharyngeal cancer de‐escalation strategies and trials: Past failures and future promise | Litcius